Serotonin 5-HT_1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs

Title:Serotonin 5-HT_1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs

Volume: 21 Issue: 26

Author(s): Andrew C. McCreary and Adrian Newman-Tancredi

Affiliation:

Keywords: Schizophrenia, 5-HT_1A, negative symptoms, cognitive symptoms, psychosis, clinical, non-clinical.

Abstract: Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT_1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT_1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT_1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT_1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT_1A agonists on neurogenesis.

Cite this article as:

McCreary C. Andrew and Newman-Tancredi Adrian, Serotonin 5-HT_1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605105215